Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $40.00 at HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN) had its target price upped by HC Wainwright from $39.00 to $40.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Enliven Therapeutics’ Q1 2026 earnings at ($0.67) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.71) EPS and Q4 2026 earnings at ($0.73) EPS.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $17.82 on Thursday. The firm has a fifty day moving average price of $18.92 and a 200 day moving average price of $21.82. The stock has a market cap of $874.36 million, a PE ratio of -9.38 and a beta of 1.07. Enliven Therapeutics has a 1-year low of $13.30 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, equities analysts expect that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the sale, the chief financial officer now owns 13,000 shares in the company, valued at $265,330. This represents a 20.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $18.39, for a total value of $122,606.13. Following the completion of the sale, the chief operating officer now directly owns 309,976 shares in the company, valued at $5,700,458.64. This trade represents a 2.11% decrease in their position. The disclosure for this sale can be found here. Insiders sold 76,111 shares of company stock valued at $1,493,145 over the last ninety days. Corporate insiders own 29.20% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Ally Bridge Group NY LLC grew its stake in Enliven Therapeutics by 19.8% in the 1st quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company’s stock worth $3,341,000 after acquiring an additional 28,064 shares during the period. Tema Etfs LLC acquired a new position in Enliven Therapeutics during the first quarter worth approximately $465,000. Quantbot Technologies LP acquired a new position in shares of Enliven Therapeutics in the 1st quarter valued at $60,000. Wellington Management Group LLP increased its holdings in shares of Enliven Therapeutics by 4.7% during the 1st quarter. Wellington Management Group LLP now owns 84,700 shares of the company’s stock worth $1,667,000 after buying an additional 3,784 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of Enliven Therapeutics by 148,550.7% in the 1st quarter. Russell Investments Group Ltd. now owns 105,542 shares of the company’s stock worth $2,077,000 after buying an additional 105,471 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.